Bayer’s Adempas meets primary endpoint in phase 4 trial in PAH patients

Bayer said that the phase 4 REPLACE trial evaluating Adempas (riociguat) in intermediate-risk adult patients with pulmonary arterial hypertension (PAH) has met its primary endpoint.